Open Access<p>Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study</p>
Author(s) -
Xiang Sun,
Yu Lan,
Xiao Yun Li,
Sai Lan Liu,
Qiu Yan Chen,
Lin Tang
Publication year - 2019
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s215190
Subject(s) - medicine , propensity score matching , nasopharyngeal carcinoma , mucositis , oncology , regimen , log rank test , cetuximab , clinical endpoint , proportional hazards model , performance status , chemotherapy , cohort , cancer , radiation therapy , clinical trial , colorectal cancer
We aimed to investigate the efficacy and safety of cetuximab (CTX) or nimotuzumab (NTZ) on the addition of palliative chemotherapy (PCT) in patients with de novo metastatic nasopharyngeal carcinoma (NPC).